Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes. In 499 LRF CLL4 cases, a trial w...

Descripción completa

Detalles Bibliográficos
Autores principales: Blakemore, Stuart J., Clifford, Ruth, Parker, Helen, Antoniou, Pavlos, Stec-Dziedzic, Ewa, Larrayoz, Marta, Davis, Zadie, Kadalyayil, Latha, Colins, Andrew, Robbe, Pauline, Vavoulis, Dimitris, Forster, Jade, Carr, Louise, Morilla, Ricardo, Else, Monica, Bryant, Dean, McCarthy, Helen, Walewska, Renata J., Steele, Andrew J., Chan, Jacqueline, Speight, Graham, Stankovic, Tanja, Cragg, Mark S., Catovsky, Daniel, Oscier, David G., Rose-Zerilli, Matthew J. J., Schuh, Anna, Strefford, Jonathan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326706/
https://www.ncbi.nlm.nih.gov/pubmed/32015491
http://dx.doi.org/10.1038/s41375-020-0723-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326706/
https://www.ncbi.nlm.nih.gov/pubmed/32015491
http://dx.doi.org/10.1038/s41375-020-0723-2

Ejemplares similares